<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kalpana Gupta, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Khalil G Ghanem, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H91340417">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urinary tract infections (UTIs) include cystitis (infection of the bladder/lower urinary tract) and pyelonephritis (infection of the kidney/upper urinary tract). The pathogenesis of UTI begins with colonization of the vaginal introitus or urethral meatus by uropathogens from the fecal flora, followed by ascension via the urethra into the bladder. Pyelonephritis develops when pathogens ascend to the kidneys via the ureters. Pyelonephritis can also be caused by seeding of the kidneys from bacteremia. It is possible that some cases of pyelonephritis are associated with seeding of the kidneys from bacteria in the lymphatics.
        </p>
        <p>
         This topic will review the approach to adults with acute complicated UTI, which we define as a UTI that has possibly extended beyond the bladder (ie, UTI with fever or other systemic symptoms, suspected or documented pyelonephritis, and UTI with sepsis or bacteremia).
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120490">
          (Related Pathway(s):
          <a class="utd-content-120490" href="/pathway/120490?topicRef=16109&amp;source=see_link">
           Urinary tract infection (UTI): Empiric antibiotic selection for acute complicated UTI in adults
          </a>
          .)
         </span>
        </p>
        <p>
         In contrast, when there are symptoms of cystitis in the absence of fever, flank pain, costovertebral angle tenderness, and other signs of systemic illness, we consider this acute simple cystitis. This approach to categorizing UTI  (
         <a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">
          table 1
         </a>
         ) differs from other conventions, as discussed in detail below.
        </p>
        <p>
         Our approaches to the diagnosis and management of acute simple cystitis (ie, cystitis symptoms in the absence of fever, flank pain, costovertebral angle tenderness, and other signs of systemic illness) and UTIs in special populations are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">
          "Urinary tract infections and asymptomatic bacteriuria in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">
          "Catheter-associated urinary tract infection in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7298.html" rel="external">
          "Urinary tract infection in kidney transplant recipients"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8053.html" rel="external">
          "Recurrent simple cystitis in women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Asymptomatic bacteriuria is also discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">
          "Asymptomatic bacteriuria in adults"
         </a>
         .)
        </p>
        <p>
         UTI in children is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5988.html" rel="external">
          "Urinary tract infections in children: Epidemiology and risk factors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6066.html" rel="external">
          "Urinary tract infections in children: Long-term management and prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5990.html" rel="external">
          "Urinary tract infections in infants and children older than one month: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5991.html" rel="external">
          "Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1932835916">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use the term acute complicated urinary tract infection (UTI) to refer to an acute UTI with any of the following features, which suggest that the infection extends beyond the bladder  (
         <a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever (&gt;99.9°F/37.7°C) – This temperature threshold is not well defined and should be individualized, taking into account baseline temperature, other potential contributors to an elevated temperature, and the risk of poor outcomes should empiric antimicrobial therapy be inappropriate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other signs or symptoms of systemic illness (including chills or rigors, significant fatigue or malaise beyond baseline).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flank pain.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Costovertebral angle tenderness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pelvic or perineal pain in men, which can suggest accompanying prostatitis. (See
         <a class="medical medical_review" href="/z/d/html/8062.html" rel="external">
          "Acute bacterial prostatitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">
          "Chronic bacterial prostatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         By this definition, pyelonephritis is a complicated UTI, regardless of patient characteristics. In the absence of any of these symptoms, we consider patients with UTI to have acute simple cystitis and manage the patient differently. (See
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males"
         </a>
         .)
        </p>
        <p>
         We do not automatically consider patients with underlying urologic abnormalities (such as nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (such as neutropenia or advanced HIV infection), or poorly controlled diabetes mellitus to have a complicated UTI if they have no concerning symptoms for upper tract or systemic infection. However, such patients can be at higher risk for more serious infection and have not traditionally been included in studies evaluating the antibiotic regimens we typically use for acute simple cystitis. Thus, we follow such patients more closely and/or have a low threshold to manage them as complicated UTI (eg, if they have subtle signs or symptoms that could be suggestive of more extensive infection). Many patients with significant urologic abnormalities come to clinical attention for UTI because of signs or symptoms consistent with complicated UTI as defined here (rather than features of simple cystitis alone).
        </p>
        <p>
         We also do not automatically consider men to have acute complicated UTI in the absence of concerning symptoms for upper tract or systemic infection. However, the possibility of prostatic involvement should always be considered in men, and this is incorporated into our approach to men with apparent simple cystitis. (See
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males"
         </a>
         .)
        </p>
        <p>
         Certain populations, such as pregnant women and renal transplant recipients, have unique management considerations and thus are not included in the above categorization. These populations are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">
          "Urinary tract infections and asymptomatic bacteriuria in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7298.html" rel="external">
          "Urinary tract infection in kidney transplant recipients"
         </a>
         .)
        </p>
        <p>
         These definitions of acute simple cystitis and complicated UTI are different from other categorizations, which themselves are somewhat variable. Specifically, cystitis or pyelonephritis in a nonpregnant premenopausal woman without underlying urologic abnormalities has traditionally been termed acute uncomplicated UTI [
         <a href="#rid1">
          1
         </a>
         ], and complicated UTI has been defined, for the purposes of treatment trials, as cystitis or pyelonephritis in a patient with underlying urologic abnormalities. Individuals who do not fit into either category have often been treated as having a complicated UTI by default. We favor an approach to treatment based on the extent of infection and severity of illness. Since complicated UTI, as defined here, is a more serious infection than simple cystitis, the efficacy of an antimicrobial agent is of greater importance, and certain agents used for simple cystitis should not be used for complicated UTI because they do not achieve adequate levels in tissue, which may be important for cure. Risk for infection with drug-resistant organisms is a consideration in antibiotic selection for both simple cystitis and acute complicated UTI.
        </p>
        <p class="headingAnchor" id="H12415021">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Escherichia coli
         </em>
         is the most frequent cause of acute complicated urinary tract infections (UTIs). Other uropathogens include other Enterobacterales (such as
         <em>
          Klebsiella
         </em>
         spp and
         <em>
          Proteus
         </em>
         spp
         <em>
          )
         </em>
         ,
         <em>
          Pseudomonas
         </em>
         , enterococci, and staphylococci (methicillin-sensitive
         <em>
          Staphylococcus aureus
         </em>
         [MSSA] and methicillin-resistant
         <em>
          S. aureus
         </em>
         [MRSA]) [
         <a href="#rid2">
          2,3
         </a>
         ]. The prevalence of particular pathogens depends partially on the host. As examples,
         <em>
          Pseudomonas
         </em>
         is more common in patients with health care exposures or instrumentation.
         <em>
          Staphylococcus saprophyticus
         </em>
         is an occasional cause of pyelonephritis in young, otherwise healthy women. UTI due to
         <em>
          Candida
         </em>
         spp is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2415.html" rel="external">
          "Candida infections of the bladder and kidneys"
         </a>
         .)
        </p>
        <p>
         Risk factors for UTI with resistant organisms include recent broad-spectrum antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant organisms are prevalent [
         <a href="#rid4">
          4-8
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Increasing rates of resistance in uropathogens have been reported globally. As an example, in the United States, one study documented a threefold increase in the prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales among hospitalized patients with UTIs from 2000 to 2009 [
         <a href="#rid9">
          9
         </a>
         ]. In another study of patients with pyelonephritis presenting to emergency departments across the United States, approximately 6 percent of the 453
         <em>
          E. coli
         </em>
         isolates produced ESBL, although rates varied by region and complicating features [
         <a href="#rid10">
          10
         </a>
         ]. In particular, a specific strain of
         <em>
          E. coli
         </em>
         , sequence type 131 (ST131), has emerged globally as a major cause of fluoroquinolone-resistant and ESBL-producing
         <em>
          E. coli
         </em>
         urinary tract infections [
         <a href="#rid11">
          11
         </a>
         ]. In one study of
         <em>
          E. coli
         </em>
         clinical isolates from extraintestinal sites, predominantly urine, collected at Veterans Affairs (VA) laboratories across the United States, the ST131 clone accounted for the majority of fluoroquinolone-resistant and ESBL isolates and was calculated to account for 28 percent of all VA
         <em>
          E. coli
         </em>
         isolates nationwide [
         <a href="#rid12">
          12
         </a>
         ]. Carbapenem resistance among Enterobacterales has also increased. (See
         <a class="medical medical_review" href="/z/d/html/469.html" rel="external">
          "Extended-spectrum beta-lactamases", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)", section on 'Overall prevalence of CRE'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12414267">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1106698204">
         <span class="h2">
          Typical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical spectrum of acute complicated urinary tract infection (UTI) encompasses both cystitis with complicating features and pyelonephritis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms and signs of cystitis include dysuria, urinary frequency and urgency, suprapubic pain, and hematuria. Patients with acute complicated UTI also have fever or other features of systemic illness (including chills, rigors, or marked fatigue or malaise beyond baseline), which suggest that infection has extended beyond the bladder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms and signs of pyelonephritis classically include fever, chills, flank pain, costovertebral angle tenderness, and nausea/vomiting [
         <a href="#rid13">
          13
         </a>
         ]. Symptoms of cystitis are often but not universally present. Atypical symptoms have also been described, with some patients complaining of pain in the epigastrium or lower abdomen.
        </p>
        <p>
        </p>
        <p>
         For men, the clinical spectrum of UTI includes prostatitis, which should be considered in men presenting with cystitis symptoms that are recurrent or are accompanied by pelvic or perineal pain. (See
         <a class="medical medical_review" href="/z/d/html/8062.html" rel="external">
          "Acute bacterial prostatitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">
          "Chronic bacterial prostatitis"
         </a>
         .)
        </p>
        <p>
         Not all patients with acute complicated UTI present with clear symptoms localizing to the urinary tract. As an example, patients with spinal cord injury and neurogenic bladder can present with autonomic dysreflexia and increased spasticity. Older or debilitated patients may present with more generalized signs or symptoms of infection (eg, fever and chills) without clear symptoms localizing to the urinary tract.
        </p>
        <p>
         Pyuria is present in almost all patients with UTI.
        </p>
        <p class="headingAnchor" id="H1992906243">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute complicated UTI can also present with bacteremia, sepsis, multiple organ system dysfunction, shock, and/or acute renal failure. This is more likely to occur in patients with urinary tract obstruction, recent urinary tract instrumentation, or other urinary tract abnormalities, and in patients who are older adults or have diabetes mellitus.
        </p>
        <p>
         Acute pyelonephritis can also be complicated by progression of the upper urinary tract infection to renal corticomedullary abscess, perinephric abscess, emphysematous pyelonephritis, or papillary necrosis. Risk factors for such complications include urinary tract obstruction and diabetes mellitus (particularly for emphysematous pyelonephritis and papillary necrosis). (See
         <a class="medical medical_review" href="/z/d/html/8057.html" rel="external">
          "Renal and perinephric abscess"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8066.html" rel="external">
          "Emphysematous urinary tract infections"
         </a>
         .)
        </p>
        <p>
         Xanthogranulomatous pyelonephritis is a rare variant of pyelonephritis in which there is massive destruction of the kidney by granulomatous tissue. Most cases occur in the setting of obstruction due to infected renal stones. Affected patients can present with weeks to months of insidious and nonspecific signs and symptoms, such as malaise, fatigue, nausea, or abdominal pain. This condition is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8058.html" rel="external">
          "Xanthogranulomatous pyelonephritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12414281">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H1421905164">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute complicated urinary tract infection (UTI) should be suspected in patients with dysuria, urinary frequency or urgency, or suprapubic pain who also have fever, chills, flank pain, pelvic or perineal pain (in men), or who otherwise appear clinically ill. Acute pyelonephritis, specifically, should be suspected in patients presenting with fever and flank pain, even in the absence of typical symptoms of cystitis. Acute complicated UTI is also often suspected in patients with nonlocalizing fever or sepsis. Evaluation includes examination to assess for other causes of illness and urine studies.
        </p>
        <p>
         Physical exam should assess for costovertebral angle, abdominal, and suprapubic tenderness. Costovertebral angle tenderness is highly suggestive of pyelonephritis although can be seen less frequently with other kidney pathology. In a retrospective study of over 3000 individuals who presented to an emergency department and had imaging findings diagnostic of pyelonephritis, 89 percent had costovertebral angle tenderness compared with 27 percent of the 62 patients who were ultimately diagnosed with renal infarct [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Among sexually active young women, a pelvic examination may be warranted, particularly if symptoms are not convincing for a UTI, to evaluate for cervical motion or uterine tenderness, which would be suggestive of pelvic inflammatory disease (see
         <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">
          "Pelvic inflammatory disease: Clinical manifestations and diagnosis", section on 'Evaluation'
         </a>
         ). Among men with symptoms of pelvic or perineal pain, cautious digital rectal examination may be warranted to evaluate for a tender or edematous prostate that would suggest acute prostatitis. (See
         <a class="medical medical_review" href="/z/d/html/8062.html" rel="external">
          "Acute bacterial prostatitis"
         </a>
         .)
        </p>
        <p>
         UTI is often suspected in older or debilitated patients who have nonspecific signs or symptoms, such as falls, change in functional status, and change in mental status. However, growing evidence indicates these are not reliable predictors of bacteriuria or UTI [
         <a href="#rid15">
          15,16
         </a>
         ] and suggests that treatment for UTI in this setting is not associated with improved outcomes [
         <a href="#rid17">
          17-19
         </a>
         ]. When these nonspecific signs or symptoms are accompanied by signs or symptoms of systemic infection or pyelonephritis, evaluation for acute complicated UTI with urine studies, in addition to a general infectious workup, is appropriate. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states", section on 'Diagnostic tests'
         </a>
         .)
        </p>
        <p>
         For all patients with suspected acute complicated UTI, we send urine for both urinalysis (either by microscopy or by dipstick) and culture with susceptibility testing. Urinalysis results inform the diagnosis. Since pyuria is present in almost all patients with UTI; its absence suggests an alternative diagnosis, particularly in patients who present with nonspecific symptoms. White cell casts, in particular, suggest a renal origin for pyuria. However, pyuria and bacteriuria may occasionally be absent if the infection does not communicate with the collecting system or if the collecting system is obstructed. Growth of bacteria on urine culture also supports the diagnosis of UTI, and susceptibility testing is essential to ensuring appropriate antimicrobial treatment. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
         Issues related to urine collection and testing as well as interpretation of urine culture colony counts are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">
          "Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults"
         </a>
         .)
        </p>
        <p>
         Pregnancy testing is appropriate in women of childbearing potential when the possibility of pregnancy cannot be reasonably excluded by history alone. Blood tests, such as general chemistry and complete blood counts, are not generally necessary unless the patient is hospitalized. Blood cultures are warranted for those who present with sepsis or severe illness or who have
         <em>
          S. aureus
         </em>
         isolated from the urine. (See
         <a class="local">
          'Regimen selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3170583666">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with acute complicated UTI do not warrant imaging studies for diagnosis or management [
         <a href="#rid20">
          20
         </a>
         ]. Imaging is generally reserved for those who are severely ill, have persistent clinical symptoms despite 48 to 72 hours of appropriate antimicrobial therapy, or have suspected urinary tract obstruction (eg, if the renal function has declined below baseline or if there is a precipitous decline in the urinary output). Imaging is also appropriate in patients who have recurrent symptoms within a few weeks of treatment.
        </p>
        <p>
         The main objective of imaging is to evaluate for a process that may delay response to therapy or warrant intervention, such as a calculus or obstruction, or to diagnose a complication of infection, such as a renal or perinephric abscess. Imaging should be obtained urgently in patients with sepsis or septic shock to identify any evidence of obstruction or abscess that requires urgent source control.
        </p>
        <p>
         Computed tomography (CT) scanning of the abdomen and pelvis (with and without contrast) is generally the study of choice to detect anatomic or physiologic factors associated with acute complicated UTI; it is more sensitive than excretory urography or renal ultrasound for detecting renal abnormalities predisposing to or caused by infection and in delineating the extent of the disease [
         <a href="#rid20">
          20-22
         </a>
         ]. CT without contrast has become the standard radiographic study for demonstrating calculi, gas-forming infections, hemorrhage, obstruction, and abscesses [
         <a href="#rid22">
          22
         </a>
         ]. Contrast is needed to demonstrate alterations in renal perfusion. CT findings of pyelonephritis include localized hypodense lesions due to ischemia induced by marked neutrophilic infiltration and edema  (
         <a class="graphic graphic_diagnosticimage graphicRef62046 graphicRef69393 graphicRef51244" href="/z/d/graphic/62046.html" rel="external">
          image 1A-C
         </a>
         ) [
         <a href="#rid21">
          21,23
         </a>
         ]. The CT can be normal in patients with mild infection [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Renal ultrasound is appropriate in patients for whom exposure to contrast or radiation is undesirable [
         <a href="#rid25">
          25
         </a>
         ]. Magnetic resonance imaging (MRI) is not advantageous over CT except when avoidance of contrast dye or ionizing radiation is warranted [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7241.html" rel="external">
          "Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">
          "Prevention of contrast-associated acute kidney injury related to angiography"
         </a>
         .)
        </p>
        <p>
         Resolution of radiographic hypodensities may lag behind clinical improvement by up to three months [
         <a href="#rid21">
          21,23,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3048399109">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of acute complicated UTI is made in the following clinical scenarios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of cystitis (dysuria, urinary urgency, and/or urinary frequency) along with fever (&gt;99.9ºF/37.7ºC) or other signs or symptoms of systemic illness, such as chills, rigors, or acute mental status changes. In such cases, pyuria and bacteriuria support the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flank pain and/or costovertebral angle tenderness in the setting of pyuria and bacteriuria. This is suggestive of pyelonephritis. Fever and typical symptoms of cystitis are usually present, but their absence does not rule out the diagnosis. CT findings that support the diagnosis include low attenuation extending to the renal capsule on contrast enhancement with or without swelling and complications such as renal abscesses. However, a normal CT does not rule out the possibility of mild pyelonephritis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever or sepsis without localizing symptoms in the setting of pyuria and bacteriuria may be attributed to UTI if other causes have been ruled out. Careful clinical assessment is necessary. The diagnosis of acute complicated UTI is unlikely if pyuria is absent.
        </p>
        <p>
        </p>
        <p>
         The presence of bacteriuria (≥10
         <sup>
          5
         </sup>
         colony-forming units/mL of a uropathogen) with or without pyuria in the absence of any symptom that could be attributable to a UTI is called asymptomatic bacteriuria and generally does not warrant treatment in nonpregnant patients who are not undergoing urologic surgery. (See
         <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">
          "Asymptomatic bacteriuria in adults"
         </a>
         .)
        </p>
        <p>
         The diagnosis of UTI in a patient with an indwelling urinary catheter is discussed in further detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">
          "Catheter-associated urinary tract infection in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         The diagnosis of bacterial prostatitis in men, which can present with similar symptoms as complicated UTI, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8062.html" rel="external">
          "Acute bacterial prostatitis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86802.html" rel="external">
          "Chronic bacterial prostatitis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12414288">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric antimicrobial therapy should be initiated promptly, taking into account risk factors for drug resistance, including previous antimicrobial use and results of recent urine cultures, with subsequent adjustment guided by antimicrobial susceptibility data. Urology should be consulted to address anatomic abnormalities if these are suspected or identified on imaging.
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120490">
          (Related Pathway(s):
          <a class="utd-content-120490" href="/pathway/120490?topicRef=16109&amp;source=see_link">
           Urinary tract infection (UTI): Empiric antibiotic selection for acute complicated UTI in adults
          </a>
          .)
         </span>
        </p>
        <p>
         Approach to management of patients diagnosed with
         <em>
          Candida
         </em>
         urinary tract infections (UTIs) is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2415.html" rel="external">
          "Candida infections of the bladder and kidneys", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3104360530">
         <span class="h2">
          Indications for hospitalization
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to admit patients with acute complicated UTI should be individualized. The decision to admit is usually clear when patients are septic or otherwise critically ill. Otherwise, general indications for inpatient management include persistently high fever (eg, &gt;38.4°C/&gt;101°F) or pain, marked debility, or inability to maintain oral hydration or take oral medications. Additionally, inpatient management is warranted when urinary tract obstruction is suspected or there are concerns regarding patient adherence.
        </p>
        <p>
         Outpatient management is acceptable for patients with acute complicated UTI of mild to moderate severity who can be stabilized, if necessary, with rehydration and antimicrobials in an outpatient facility or the emergency department and discharged on oral antimicrobials with close follow-up.
        </p>
        <p>
         Many patients can be managed in the outpatient setting. As an example, in a study of 44 patients with pyelonephritis but no major comorbidities, a 12-hour observation period with parenteral antimicrobial therapy in the emergency department followed by completion of outpatient oral antimicrobials was effective management for 97 percent of patients [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2417976538">
         <span class="h2">
          Empiric antimicrobial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to empiric therapy of acute complicated UTI depends on the severity of illness, the risk factors for resistant pathogens, and specific host factors [
         <a href="#rid1">
          1
         </a>
         ]. The choice among the options presented for each population depends on susceptibility of prior urinary isolates, patient circumstances (such as allergy or expected tolerability, history of prior antimicrobial use), local community resistance prevalence of Enterobacterales (if known), and drug toxicity, interactions, availability, and cost  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ).
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-120490">
          (Related Pathway(s):
          <a class="utd-content-120490" href="/pathway/120490?topicRef=16109&amp;source=see_link">
           Urinary tract infection (UTI): Empiric antibiotic selection for acute complicated UTI in adults
          </a>
          .)
         </span>
        </p>
        <p>
         Urine culture and susceptibility testing should be performed in all patients, and the initial empiric regimen should be tailored appropriately to the susceptibility profile of the infecting pathogen, once known [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         Data evaluating the efficacy of various regimens for acute complicated UTI are limited, and only a small number of different regimens have been formally evaluated [
         <a href="#rid29">
          29,30
         </a>
         ]. The recommendations in this section are based instead on the expected microbial spectrum of antimicrobial agents that achieve adequate urinary tract and systemic levels.
        </p>
        <p class="headingAnchor" id="H1551581455">
         <span class="h3">
          Critical illness and/or urinary tract obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use a broad-spectrum antimicrobial regimen for empiric therapy of patients with acute complicated UTI who are critically ill (ie, with severe sepsis or otherwise warranting intensive care unit admission), getting worse on current therapy, or who have suspected urinary tract obstruction (eg, if the renal function has declined below baseline or if there is a decline in urine output)  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         In such patients, we suggest an antipseudomonal carbapenem (
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         500 mg intravenously [IV] every six hours or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         1 g IV every eight hours) to cover extended-spectrum beta-lactamase (ESBL)-producing organisms and
         <em>
          Pseudomonas aeruginosa
         </em>
         , as well as
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         to cover methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA).
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          Daptomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         are alternatives to vancomycin. However, the selection of antimicrobial therapy should be individualized. In locations where the community prevalence of multidrug-resistant organisms (in particular, ESBL-producing organisms) is low, regimens with a narrower spectrum may be appropriate. In such cases, regimen selection can be based on individual risk of resistance, as discussed elsewhere. (See
         <a class="local">
          'Other hospitalized patients'
         </a>
         below.)
        </p>
        <p>
         The rationale for broad coverage in the setting of critical illness or obstruction is the high risk of adverse outcomes should empiric antimicrobial therapy be insufficient and the increasing prevalence of multidrug-resistant organisms, even in the general population (see
         <a class="local">
          'Microbiology'
         </a>
         above). Patients who have a UTI in the setting of urinary tract obstruction are at a particularly high risk of clinical decompensation. When broad-spectrum regimens are used empirically, it is important to tailor the regimen if culture and susceptibility testing indicate that a narrower agent would be active. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         Advanced cephalosporin or carbapenem combinations with beta-lactamase inhibitors, the novel cephalosporin
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         , the advanced aminoglycoside
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         , and parenteral
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         also have activity against some ESBL-producing Enterobacterales and, in some cases, multidrug-resistant
         <em>
          P. aeruginosa
         </em>
         isolates and are effective for acute complicated UTI [
         <a href="#rid31">
          31-35
         </a>
         ]; however, because of cost and antimicrobial stewardship concerns, as well as limited data for some of the agents, they should only be used in select cases of highly resistant infections. If carbapenem resistance is suspected based on prior susceptibility testing results, an infectious diseases consult should be obtained. (See
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)", section on 'Approach to treatment'
         </a>
         .)
        </p>
        <p>
         Patients with critical illness or obstruction also warrant imaging to evaluate for obstruction or other complications that may warrant intervention. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
         Results of urine culture and susceptibility testing should be followed to ensure that the chosen empiric antimicrobial regimen is appropriate and to guide selection of definitive therapy. If feasible, antibiotics with a narrow spectrum of activity should be chosen to complete the antibiotic course. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4071370685">
         <span class="h3">
          Other hospitalized patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are hospitalized for acute complicated UTI (see
         <a class="local">
          'Indications for hospitalization'
         </a>
         above) but are not critically ill and do not have suspected urinary tract obstruction, our approach to empiric antimicrobial regimen selection depends on the risk for infection with multidrug-resistant gram-negative organisms  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No risk factors for infection with a multidrug-resistant gram-negative
         </strong>
         <strong>
          organism
         </strong>
         (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ) – For these patients, we favor
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (1 g IV once daily) for parenteral treatment because of its safety profile and narrow spectrum compared with other parenteral agents  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         ). Oral or parenteral fluoroquinolones (
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ) are also reasonable alternatives if the patient has not had a urinary isolate resistant to fluoroquinolones in the prior three months and the community prevalence of
         <em>
          E. coli
         </em>
         fluoroquinolone resistance is not known to be higher than 10 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concern for particular pathogens should further inform antibiotic selection. If
         <em>
          Enterococcus
         </em>
         species are suspected (eg, because of prior urinary isolates),
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         can be used because it has activity against these organisms in addition to typical gram-negative pathogens. If drug-resistant gram-positive organisms are suspected because of previous urinary isolates or other risk factors,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (for MRSA) or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         (for vancomycin-resistant
         <em>
          Enterococcus
         </em>
         [VRE]) should be added to the gram-negative agent (eg,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ). If there is a risk of
         <em>
          P. aeruginosa
         </em>
         (eg, because of prior urinary isolates or febrile neutropenia), piperacillin-tazobactam,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , or a fluoroquinolone are appropriate options.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          At least one
         </strong>
         <strong>
          risk factor for infection with a multidrug-resistant gram-negative
         </strong>
         <strong>
          organism
         </strong>
         (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ) – For these patients, we favor empiric treatment with
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         3.375 g IV every six hours,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         2 g IV every 12 hours, or an antipseudomonal carbapenem (
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         500 mg IV every six hours or
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         1 g IV every eight hours)  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concern for particular pathogens should further inform regimen selection. If patients have risk factors for an ESBL-producing organism, we avoid
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , and for those with recent (eg, within the prior three months) history of infection with ESBL-producing organisms, we specifically choose a carbapenem. If resistant
         <em>
          Enterococcus
         </em>
         species or MRSA are suspected (eg, because of prior urinary isolates), we add
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (for MRSA) or
         <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">
          daptomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         (for vancomycin-resistant
         <em>
          Enterococcus
         </em>
         [VRE]). All the listed options have activity against
         <em>
          P. aeruginosa
         </em>
         ;
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         (2 g IV every eight hours) is another antipseudomonal agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If available (not in the United States), parenteral
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is also effective for complicated UTI and has activity against certain MDR organisms, such as ESBL-producing organisms [
         <a href="#rid35">
          35
         </a>
         ]; we would reserve this agent as an alternative to carbapenems as more widespread use could promote resistance, decreasing the utility of oral fosfomycin. Additionally, it may not be tolerated as well as other agents [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advanced cephalosporin or carbapenem combinations with beta-lactamase inhibitors and the novel cephalosporin
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         also have activity against some ESBL-producing Enterobacterales and, in some cases, multidrug-resistant
         <em>
          P. aeruginosa
         </em>
         isolates and are effective for acute complicated UTI [
         <a href="#rid31">
          31-34
         </a>
         ]; however, because of cost and antimicrobial stewardship concerns, they should only be used in select cases of highly resistant infections [
         <a href="#rid37">
          37
         </a>
         ]. If carbapenem resistance (or otherwise extensive drug resistance) is suspected based on prior susceptibility testing results, an infectious diseases consult should be obtained. Treatment of carbapenem-resistant Enterobacterales and extensively drug-resistant
         <em>
          Pseudomonas
         </em>
         is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)", section on 'Approach to treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Management of multidrug-resistant organisms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Results of urine culture and susceptibility testing should be followed to ensure that the chosen empiric antimicrobial regimen is appropriate and to guide selection of definitive therapy. If feasible, antibiotics with a narrow spectrum of activity should be chosen to complete the antibiotic course. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1769504182">
         <span class="h3">
          Outpatients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute complicated UTI of mild to moderate severity who can take oral medications reliably can be treated in the outpatient setting. The approach to selection of an empiric outpatient antimicrobial regimen depends on the risk factors for infection with a multidrug-resistant organism (in particular ESBL-producing isolates)  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ). Recommended regimens are outlined below. (See
         <a class="local">
          'Low risk of MDR infection'
         </a>
         below and
         <a class="local">
          'High risk of MDR infection'
         </a>
         below.)
        </p>
        <p>
         Whether fluoroquinolones can be used (accounting for contraindications or concerns for fluoroquinolone resistance specifically) is also an important consideration in regimen selection. In the absence of resistance, fluoroquinolones provide a broad spectrum of antimicrobial activity against most uropathogens (including
         <em>
          P. aeruginosa
         </em>
         ) and achieve high levels in the urinary tract. Studies of acute complicated UTI have shown that the fluoroquinolones are generally comparable or superior to other broad-spectrum antimicrobials, including parenteral regimens [
         <a href="#rid29">
          29,38
         </a>
         ]. However, increasing rates of resistance to fluoroquinolones among uropathogens, even among outpatients, are diminishing their value for this purpose [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">
          "Acute simple cystitis in adult and adolescent females", section on 'Resistance trends in E. coli'
         </a>
         .)
        </p>
        <p>
         When a fluoroquinolone can be used,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         are the most common agents. Other less commonly used fluoroquinolones that are effective for UTIs include
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          norfloxacin
         </a>
         .
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          Moxifloxacin
         </a>
         attains lower urinary levels than other fluoroquinolones and should not be used.
        </p>
        <p>
         Although there are concerns about the potential adverse effects, including
         <em>
          Clostridioides difficile
         </em>
         infection and ecological effects (ie, selection of resistant organisms) caused by the fluoroquinolones, their benefits are thought to outweigh their risks for acute complicated UTI.
        </p>
        <p class="headingAnchor" id="H2493517473">
         <span class="h4">
          Low risk of MDR infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For outpatients with acute complicated UTI and no risk factors for infection with a multidrug-resistant (MDR) gram-negative organism  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), empiric antimicrobial regimen selection depends on contraindications to or other concerns with fluoroquinolones  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ). These include allergy or intolerance to the fluoroquinolone class (including prolonged QT interval or other risk factors for torsades de pointes) or an unmodifiable drug interaction. Because of the prevalence of fluoroquinolone resistance and underlying comorbidities associated with adverse effects, fluoroquinolone-sparing regimens are often an appropriate option.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoroquinolone-based regimens
         </strong>
         – For patients who have no contraindications to fluoroquinolones and are at low personal risk for a fluoroquinolone-resistant isolate  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), we suggest an oral fluoroquinolone for empiric therapy. Appropriate regimens include
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         500 mg twice daily, ciprofloxacin 1000 mg extended release once daily, or
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         750 mg once daily [
         <a href="#rid40">
          40-44
         </a>
         ]. Fluoroquinolones are given for five to seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the case that community prevalence of
         <em>
          E. coli
         </em>
         fluoroquinolone resistance is known to be higher than 10 percent, we suggest a single dose of a long-acting parenteral agent prior to administering the fluoroquinolone [
         <a href="#rid45">
          45
         </a>
         ]. We prefer
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (1 g IV or intramuscular [IM] once) because of its safety, efficacy, and microbial spectrum.
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          Ertapenem
         </a>
         (1 g IV or IM once) is an alternative for patients with an allergy that precludes ceftriaxone use or expected resistance to ceftriaxone, and aminoglycosides (
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         5 mg per kg IV or IM once) are reserved for patients who cannot use the other two. Since timely use of an agent with in vitro activity is essential to treat acute complicated UTI and minimize progression of infection, the threshold for selecting an antimicrobial for empiric broad-spectrum therapy should be set at a relatively low resistance prevalence. For fluoroquinolones, a resistance prevalence of 10 percent has been suggested based on expert opinion [
         <a href="#rid1">
          1
         </a>
         ]. However, in an outpatient who is not severely ill and has low personal risk of MDR, avoiding a fluoroquinolone altogether because of resistance concerns is not necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefits of fluoroquinolones are thought to outweigh their risks for acute complicated UTI, but patients should be advised about the uncommon but potentially serious musculoskeletal and neurologic adverse effects associated with fluoroquinolones. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoroquinolone-sparing regimens
         </strong>
         – For patients who have contraindications to fluoroquinolones or other concerns about fluoroquinolone use, our approach depends on the relative severity of illness. For those with mild infection, we use a single dose of a long-acting parenteral agent followed by a non-fluoroquinolone oral agent [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As above, we prefer
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (1 g IV or IM once) as a long-acting parenteral agent because of its safety, efficacy, and microbial spectrum.
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          Ertapenem
         </a>
         (1 g IV or IM once) is an alternative for patients with an allergy that precludes ceftriaxone use or expected resistance to ceftriaxone, and aminoglycosides (
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         5 mg per kg IV or IM once) are reserved for patients who cannot use the other two.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following the dose of the parenteral agent, options include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          Trimethoprim-sulfamethoxazole
         </a>
         – one double-strength (160 mg/800 mg) tablet orally twice daily for 7 to 10 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          Amoxicillin-clavulanate
         </a>
         – 875 mg orally twice daily for 7 to 10 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          Cefpodoxime
         </a>
         – 200 mg orally twice daily for 7 to 10 days
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          Cefadroxil
         </a>
         – 1 g orally twice daily for 7 to 10 days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice among those should be guided by the susceptibility of prior urinary isolates and resistance rates in the community. We do not typically use
         <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">
          cefdinir
         </a>
         for patients with complicated UTI because it has low bioavailability, achieves only 10 to 20 percent urinary concentration, and does not offer an advantage over
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          cefpodoxime
         </a>
         . However, if no other options are available, some data suggest that it achieves high clinical response rates as a step down option following parenteral
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For outpatients who are systemically ill or are at risk for more severe illness, we favor continuing the parenteral therapy until culture and susceptibility testing results can guide selection of an appropriate oral agent.
        </p>
        <p>
        </p>
        <p>
         Results of urine culture and susceptibility testing should be followed to ensure that the chosen empiric antimicrobial regimen is appropriate and to guide modification of the regimen, if necessary. The durations of therapy listed above assume that the patient is appropriately responding to antibiotic therapy; longer durations or re-evaluation may be warranted in those who are slow to respond. These issues are discussed in detail elsewhere. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         In some cases, results of urine culture and susceptibility testing may be known at the time of treatment initiation. For those with mild illness caused by a susceptible pathogen, oral therapy selected based on susceptibility testing without initial parenteral therapy is reasonable. Potential regimens are discussed elsewhere. (See
         <a class="local">
          'Regimen selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H486606063">
         <span class="h4">
          High risk of MDR infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For outpatients with acute complicated UTI and risk factors for infection with a multidrug-resistant (MDR) gram-negative organism  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), we suggest giving an initial dose of
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         1 g IV or IM  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ).
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          Plazomicin
         </a>
         is a potential alternative in this setting; clinical experience with this agent is limited.
        </p>
        <p>
         For patients who have no contraindications to fluoroquinolones (ie, allergy or expected intolerability, including risk factors for torsades de pointes, or unmodifiable drug interaction) and have not had fluoroquinolone use or a fluoroquinolone-resistant urinary isolate in the prior three months, we follow this dose of
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         with a fluoroquinolone. Appropriate regimens include
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         500 mg twice daily, ciprofloxacin 1000 mg extended release once daily, and
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         750 mg once daily [
         <a href="#rid40">
          40-44
         </a>
         ]. Fluoroquinolones are given for five to seven days. The benefits of fluoroquinolones for acute complicated UTI are thought to outweigh their risks, but patients should be advised about the uncommon but potentially serious musculoskeletal and neurologic adverse effects associated with fluoroquinolones. (See
         <a class="medical medical_review" href="/z/d/html/490.html" rel="external">
          "Fluoroquinolones", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         For patients who have either contraindications or concern for fluoroquinolone resistance, we instead continue to administer
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         1 g IV or IM daily in the outpatient setting until culture and susceptibility testing results return. As above, once-daily
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         is a potential alternative; dosing and toxicity monitoring are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/475.html" rel="external">
          "Dosing and administration of parenteral aminoglycosides", section on 'Plazomicin'
         </a>
         .)
        </p>
        <p>
         Once available, culture and susceptibility testing results should guide selection of definitive therapy. (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H945200358">
         <span class="h2">
          Directed antimicrobial therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3657009619">
         <span class="h3">
          Regimen selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Results of urine culture and susceptibility testing should be used to tailor the regimen, if appropriate. In many cases, broad-spectrum empiric regimens can be replaced by a more narrow-spectrum agent. Patients who were initially treated with a parenteral regimen can be switched to an oral agent once symptoms have improved, as long as culture and susceptibility testing allow. Options depend on the pathogen identified:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enterobacterales
         </strong>
         <strong>
          (eg,
         </strong>
         <strong>
          <em>
           E. coli
          </em>
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          <em>
           K. pneumoniae
          </em>
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          <em>
           P. mirabilis
          </em>
         </strong>
         <strong>
          ):
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Susceptible isolates
         </strong>
         – For susceptible Enterobacterales, appropriate oral agents to treat acute complicated UTI include
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         (750 mg once daily),
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (500 mg twice daily or 1000 extended release once daily), and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (one double-strength [160 mg/800 mg] tablet orally twice daily) [
         <a href="#rid40">
          40-42
         </a>
         ]. Oral beta-lactams (eg,
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         875 mg orally twice daily,
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          cefpodoxime
         </a>
         200 mg orally twice daily,
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         1 g orally twice daily) may be less effective for acute complicated UTI (based on cystitis studies) but are appropriate alternatives if susceptibility is documented and the other agents are not feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Resistant isolates
         </strong>
         – Some isolates that are resistant to beta-lactams (eg, ESBL-producing Enterobacterales) may still be susceptible to fluoroquinolones and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , in which case those agents can be used orally as above. However, for Enterobacterales that are resistant to fluoroquinolones, trimethoprim-sulfamethoxazole, and oral beta-lactams, a parenteral agent is generally needed to complete the course of treatment. We use the most narrow-spectrum agent that has expected activity. For ESBL-producing bacteria, this is usually a carbapenem (
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , or
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         ). The drawbacks to using
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         for ESBL-producing bacteria are discussed elsewhere. Treatment of carbapenem-resistant gram-negative bacteria is also discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/469.html" rel="external">
          "Extended-spectrum beta-lactamases", section on 'Treatment options'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/471.html" rel="external">
          "Carbapenem-resistant
          <i>
           E. coli
          </i>
          ,
          <i>
           K. pneumoniae
          </i>
          , and other Enterobacterales (CRE)", section on 'Approach to treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Options for outpatient administration of parenteral antimicrobials include use of a peripherally inserted central catheter, a pre-existing central catheter, or IM injection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          Nitrofurantoin
         </a>
         , oral
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">
          pivmecillinam
         </a>
         should generally be avoided in the setting of acute complicated UTI because they do not achieve adequate tissue levels outside the bladder [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Novel options for outpatient management of resistant gram-negative bacteria are needed. In a randomized trial that included 868 adults hospitalized for complicated UTI, an experimental oral carbapenem, tebipenem, resulted in similar clinical cure rates as intravenous
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         , each given for 7 to 10 days (93 versus 94 percent at day 19) [
         <a href="#rid47">
          47
         </a>
         ]. Microbiologic cure rates were lower with tebipenem for ESBL-producing organisms, but clinical response with these pathogens remained high. While a promising agent, the risk of selecting for carbapenem resistance is a concern and judicious use, if available in the future, will be important.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Enterococcus
          </em>
         </strong>
         – If
         <em>
          Enterococcus
         </em>
         is isolated,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (500 mg orally every eight hours or 875 mg twice daily) is the agent of choice if the organism is susceptible; other UpToDate contributors favor a higher dose of amoxicillin in this setting [
         <a href="#rid48">
          48,49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">
          "Treatment of enterococcal infections", section on 'Urinary tract infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         – Directed therapy of
         <em>
          Pseudomonas
         </em>
         UTI is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3148.html" rel="external">
          "Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Staphylococcus
          </em>
         </strong>
         – Oral options include
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (one double-strength [160 mg/800 mg] tablet orally twice daily) or, for methicillin-susceptible
         <em>
          Staphylococcus
         </em>
         species,
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         (500 mg twice daily).
         <em>
          S. aureus
         </em>
         is a relatively uncommon urinary isolate. When
         <em>
          S. aureus
         </em>
         is isolated from the urine in a patient with complicated UTI, blood cultures are warranted to rule out bacteremia; we typically obtain two sets of cultures. The urinary tract can be the original source of
         <em>
          S. aureus
         </em>
         bacteremia or a secondary site seeded from hematogenous spread. The reported rate of concurrent or subsequent bacteremia in patients with
         <em>
          S. aureus
         </em>
         bacteriuria varies between approximately 5 and 20 percent [
         <a href="#rid50">
          50-52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">
          "Clinical manifestations of Staphylococcus aureus infection in adults", section on 'Bacteriuria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1613710760">
         <span class="h3">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total duration of antimicrobial therapy generally ranges from 5 to 10 days, depending on the rapidity of clinical response and the antimicrobial chosen to complete the course. For individuals who have an appropriate clinical response (symptomatic improvement within the first 48 to 72 hours of therapy), we give fluoroquinolones for 5 to 7 days,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         for 7 to 10 days [
         <a href="#rid53">
          53
         </a>
         ], and beta-lactams for 7 to 10 days. For those who have slow response to appropriate antibiotic therapy (eg, no symptomatic improvement within the first 48 to 72 hours of therapy), evaluation should assess for infectious complications or for underlying anatomic abnormalities that could delay response (see
         <a class="local">
          'Imaging'
         </a>
         above). Longer antibiotic durations may be warranted in patients who have a nidus of infection (such as a nonobstructing stone) that cannot be removed. The duration of antimicrobial therapy need not be extended in the setting of bacteremia when other complicating factors are absent; there is no evidence that bacteremia portends a worse prognosis [
         <a href="#rid54">
          54,55
         </a>
         ]. A potential exception is
         <em>
          S. aureus
         </em>
         bacteremia, which is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">
          "Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Clinical approach'
         </a>
         .)
        </p>
        <p>
         Several systematic reviews and meta-analyses of randomized trials have suggested that shorter antibiotic courses (seven days or fewer) for complicated UTI result in similar clinical cure rates compared with longer courses [
         <a href="#rid56">
          56-58
         </a>
         ]. Most of these data come from randomized trials of fluoroquinolones, in which five- or seven-day regimens of fluoroquinolones were comparable to longer durations [
         <a href="#rid41">
          41,43,59
         </a>
         ]. Although one randomized trial among males with complicated UTI suggested lower rates of microbiologic response with 7 versus 14 days of fluoroquinolone therapy, clinical response rates were similar [
         <a href="#rid60">
          60
         </a>
         ]. Data are more limited for other antibiotic classes, and studies evaluating beta-lactams included older agents that are not commonly used for UTI. Nevertheless, those studies failed to identify a clear clinical benefit to treating longer than 10 days [
         <a href="#rid55">
          55,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4047304728">
         <span class="h2">
          Addressing underlying urinary tract abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to antimicrobial therapy, the possibility of urinary obstruction should be considered and managed, if identified. Patients who have underlying anatomical or functional urinary tract abnormalities (including neurogenic bladder, indwelling bladder catheters, nephrostomy tubes, urethral stents) may warrant additional management, such as more frequent catheterization to improve urinary flow, exchange or removal of a catheter, and/or urologic or gynecologic consultation. Antimicrobials alone may not be successful unless such underlying conditions are corrected [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">
          "Catheter-associated urinary tract infection in adults", section on 'Catheter management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1558116588">
         <span class="h2">
          Follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms should improve promptly if antimicrobial therapy is effective. Among patients treated as outpatients, those who had pyelonephritis should have close follow-up either face-to-face or by telephone within 48 to 72 hours.
        </p>
        <p>
         Any patients who have worsening symptoms following initiation of antimicrobials, persistent symptoms after 48 to 72 hours of appropriate antimicrobial therapy, or recurrent symptoms within a few weeks of treatment should have additional evaluation, including abdominal/pelvic imaging (generally with computed tomography if not already performed) for factors that might be compromising clinical response. Urine culture and susceptibility testing should be repeated, and treatment should be tailored to the susceptibility profile of other causative organisms isolated.
        </p>
        <p>
         For patients who had hematuria on initial presentation, a urinalysis should be repeated several weeks following antimicrobial therapy to evaluate for persistent hematuria. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'Overall approach to the evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4100199031">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111611.html" rel="external">
          "Society guideline links: Urinary tract infections in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25677696">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4016.html" rel="external">
          "Patient education: Urinary tract infections in adolescents and adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2923745">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – We use the term acute complicated urinary tract infection (UTI) to refer to an acute UTI with any features that suggest that the infection extends beyond the bladder  (
         <a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">
          table 1
         </a>
         ). These include fever (eg, &gt;99.9°F/37.7°C), other signs or symptoms of systemic illness (including chills, rigors, or altered mental status), flank pain, and costovertebral angle tenderness. By this definition, pyelonephritis is a complicated UTI, regardless of patient characteristics. (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do not consider patients with underlying urologic abnormalities (eg, nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (eg, neutropenia or advanced HIV), or poorly controlled diabetes mellitus to have complicated UTI if they have no concerning symptoms for upper tract or systemic infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Relevant uropathogens include primarily
         <em>
          Escherichia coli
         </em>
         , but also other Enterobacterales, other gram-negative bacilli (including
         <em>
          Pseudomonas aeruginosa
         </em>
         ), staphylococci, enterococci, and
         <em>
          Candida
         </em>
         species. Risk factors for resistant organisms include recent broad-spectrum antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant organisms are prevalent  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Patients with complicated UTI can have symptoms of cystitis (eg, dysuria, urinary frequency, urinary urgency, suprapubic pain) plus fever or other features of systemic illness (eg, chills, rigors, or new marked fatigue or malaise). Alternatively, they may have more prominent features of pyelonephritis, which classically include fever, chills, flank pain, costovertebral angle tenderness, and nausea/vomiting, with or without symptoms of cystitis. In males, pelvic or perineal pain accompanying urinary symptoms suggests prostatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Acute complicated UTI can also present with bacteremia, sepsis, multiple organ system dysfunction, shock, and/or acute kidney failure. This is more likely to occur in patients with urinary tract obstruction, recent urinary tract instrumentation, or other urinary tract abnormalities, and in older adults or patients with diabetes mellitus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On urine studies, pyuria and bacteriuria are almost always present. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         <strong>
          and diagnosis
         </strong>
         – For all patients with suspected acute complicated UTI, we send urine for both urinalysis (either by microscopy or by dipstick) and culture with susceptibility testing. The diagnosis is made in patients who have consistent clinical findings (eg, signs and symptoms of pyelonephritis or of cystitis with features of systemic infection) as well as pyuria and bacteriuria. Fever or sepsis without localizing symptoms in the setting of pyuria and bacteriuria can also be attributed to complicated UTI if other causes have been ruled out.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The absence of pyuria suggests an alternative diagnosis, particularly if symptoms are nonspecific  (
         <a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">
          table 4
         </a>
         ). Imaging is generally reserved for those who are severely ill, have suspected urinary tract obstruction, have persistent symptoms despite 48 to 72 hours of appropriate antimicrobial therapy, or have recurrent symptoms. (See
         <a class="local">
          'Evaluation'
         </a>
         above and
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for hospitalization
         </strong>
         – Indications for inpatient management include sepsis or critical illness, persistently high fever (eg, &gt;38.4°C/&gt;101°F) or pain, marked debility, suspected urinary tract obstruction (eg, due to nephrolithiasis), concern about medication adherence, and inability to maintain oral hydration or take oral medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Outpatient management is appropriate for others, including those who can be stabilized with initial treatment (eg, rehydration and antimicrobials) in an outpatient facility or the emergency department. (See
         <a class="local">
          'Indications for hospitalization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Empiric therapy
         </strong>
         – The approach to empiric therapy of acute complicated UTI depends on the severity of illness, the risk factors for resistant pathogens, and specific host factors  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Empiric antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Critical illness/urinary tract obstruction
         </strong>
         – For patients who are critically ill or have urinary tract obstruction, we suggest an antipseudomonal carbapenem (
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         or
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ) plus
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). These patients are at high risk of adverse outcomes if empiric antimicrobial therapy is insufficient, and these regimens cover multidrug-resistant organisms, which are increasing in prevalence. In locations where the community prevalence of multidrug-resistant organisms is known to be low, regimens with a narrower spectrum (as suggested for other hospitalized patients) may be appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Urinary tract obstruction, if present, requires decompression. (See
         <a class="local">
          'Critical illness and/or urinary tract obstruction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other hospitalized patients
         </strong>
         – For hospitalized patients without critical illness or urinary tract obstruction who have
         <strong>
          no
         </strong>
         risk factors for a multidrug-resistant (MDR) gram-negative infection  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), we suggest
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef115994" href="/z/d/graphic/115994.html" rel="external">
          algorithm 1
         </a>
         )(
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Oral or parenteral fluoroquinolones are also reasonable options. For patients who have risk factors for an MDR gram-negative infection, we suggest
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , or an antipseudomonal carbapenem (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For those with a recent history of an extended-spectrum beta lactamase (ESBL)-producing urinary isolate specifically, we use a carbapenem. (See
         <a class="local">
          'Other hospitalized patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatients without risk for resistance
         </strong>
         – For outpatients without risk factors for an MDR gram-negative infection  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), we suggest an oral fluoroquinolone, such as
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). If the community prevalence of
         <em>
          E. coli
         </em>
         fluoroquinolone resistance is known to be higher than 10 percent, we also suggest a single dose of a long-acting parenteral agent such as
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         prior to administering the fluoroquinolone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If there are concerns about intolerance or adverse effects with fluoroquinolones, other options include giving a long-acting parenteral agent followed by either
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         or an oral beta-lactam, or continuing the parenteral agent until susceptibility testing results return. (See
         <a class="local">
          'Low risk of MDR infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatients with risk for resistance
         </strong>
         – For outpatients with risk factors for an MDR gram-negative infection  (
         <a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">
          table 2
         </a>
         ), we suggest an initial dose of
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef116091" href="/z/d/graphic/116091.html" rel="external">
          algorithm 2
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Subsequently, an oral fluoroquinolone or daily ertapenem can be used. (See
         <a class="local">
          'High risk of MDR infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Directed therapy and duration
         </strong>
         – Urine culture and susceptibility testing results should be used to tailor the regimen to a more narrow-spectrum agent, if appropriate. Parenteral regimens can also be switched to an active oral agent following symptom improvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Appropriate oral agents to treat acute complicated UTI include fluoroquinolones (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) for 5 to 7 days or
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         for 7 to 10 days. Oral beta-lactams (eg,
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          cefpodoxime
         </a>
         , or
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         ) for 7 to 10 days are less effective for acute complicated UTI but are appropriate alternatives if susceptibility is documented and the other agents are not feasible. Doses are the same as those listed in the table  (
         <a class="graphic graphic_table graphicRef131022" href="/z/d/graphic/131022.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Directed antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urologic issues
         </strong>
         – Patients who have underlying anatomical or functional urinary tract abnormalities (including neurogenic bladder, indwelling bladder catheters, nephrostomy tubes, urethral stents) may warrant additional management, such as more frequent catheterization to improve urinary flow, exchange or removal of a catheter, and/or urologic or gynecologic consultation. (See
         <a class="local">
          'Addressing underlying urinary tract abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H338513989">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thomas M Hooton, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging 2001; 18:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Emerg Med Int 2013; 2013:258517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker E, Lyman A, Gupta K, et al. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis 2016; 63:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smithson A, Chico C, Ramos J, et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 2012; 31:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linsenmeyer K, Strymish J, Gupta K. Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections. Antimicrob Agents Chemother 2015; 59:7593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013; 34:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talan DA, Takhar SS, Krishnadasan A, et al. Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1). Emerg Infect Dis 2016; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin Infect Dis 2013; 57:1266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013; 57:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley KF, Carson NE, Gutch RC, et al. Site of infection in acute urinary-tract infection in general practice. Lancet 1971; 2:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo S, Seo D, Cho YS, et al. Clinical factors distinguishing renal infarction from acute pyelonephritis: A randomly matched retrospective case-control study. Am J Emerg Med 2023; 72:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potts L, Cross S, MacLennan WJ, Watt B. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr 1996; 23:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasgupta M, Brymer C, Elsayed S. Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study. Arch Gerontol Geriatr 2017; 72:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundvall PD, Elm M, Ulleryd P, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr 2014; 14:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract 2011; 12:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petty LA, Vaughn VM, Flanders SA, et al. Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. JAMA Intern Med 2019; 179:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Expert Panel on Urological Imaging, Smith AD, Nikolaidis P, et al. ACR Appropriateness Criteria® Acute Pyelonephritis: 2022 Update. J Am Coll Radiol 2022; 19:S224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyrier A, Condamin MC, Fernet M, et al. Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int 1989; 35:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawashima A, LeRoy AJ. Radiologic evaluation of patients with renal infections. Infect Dis Clin North Am 2003; 17:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsugaya M, Hirao N, Sakagami H, et al. Computerized tomography in acute pyelonephritis: the clinical correlations. J Urol 1990; 144:611.
          </a>
         </li>
         <li class="breakAll">
          Brandt WE. Adrenal glands and kidneys. In: Fundamentals of Diagnostic Radiology, Bryant WE and Helms CA (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2012.
         </li>
         <li class="breakAll">
          http://www.guideline.gov/summary/summary.aspx?doc_id=13683&amp;nbr=007017&amp;string=pyelonephritis (Accessed on September 14, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demertzis J, Menias CO. State of the art: imaging of renal infections. Emerg Radiol 2007; 14:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soulen MC, Fishman EK, Goldman SM. Sequelae of acute renal infections: CT evaluation. Radiology 1989; 173:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward G, Jorden RC, Severance HW. Treatment of pyelonephritis in an observation unit. Ann Emerg Med 1991; 20:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh KP, Li G, Mitrani-Gold FS, et al. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrob Agents Chemother 2013; 57:5284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis 2015; 15:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 2017; 72:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019; 380:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis 2019; 69:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, et al. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2137277.
          </a>
         </li>
         <li class="breakAll">
          Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0. https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed on June 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000; 283:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008; 71:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talan DA, Klimberg IW, Nicolle LE, et al. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004; 171:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012; 380:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vellinga A, Tansey S, Hanahoe B, et al. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model. J Antimicrob Chemother 2012; 67:2523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez M, Collvinent B, Miró O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J 2002; 19:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lojanapiwat B, Nimitvilai S, Bamroongya M, et al. Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial. Infect Drug Resist 2019; 12:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckburg PB, Muir L, Critchley IA, et al. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med 2022; 386:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah KJ, Cherabuddi K, Shultz J, et al. Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience. Int J Antimicrob Agents 2018; 51:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole KA, Kenney RM, Perri MB, et al. Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections. Antimicrob Agents Chemother 2015; 59:7362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stokes W, Parkins MD, Parfitt ECT, et al. Incidence and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study. Clin Infect Dis 2019; 69:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson DJ, Kaye KS, Sexton DJ. Methicillin-resistant Staphylococcus aureus bacteremia after isolation from urine. Clin Infect Dis 2006; 42:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karakonstantis S, Kalemaki D. Evaluation and management of Staphylococcus aureus bacteriuria: an updated review. Infection 2018; 46:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med 1999; 159:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAteer J, Lee JH, Cosgrove SE, et al. Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia. Clin Infect Dis 2023; 76:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erba L, Furlan L, Monti A, et al. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. Intern Emerg Med 2021; 16:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanretty AM, Gallagher JC. Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. Pharmacotherapy 2018; 38:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Nieuwkoop C, van der Starre WE, Stalenhoef JE, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med 2017; 15:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafaurie M, Chevret S, Fontaine JP, et al. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Clin Infect Dis 2023; 76:2154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolle LE. A practical guide to the management of complicated urinary tract infection. Drugs 1997; 53:583.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16109 Version 68.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21292654" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17599303" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Population-based epidemiologic analysis of acute pyelonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11341472" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A practical guide to antimicrobial management of complicated urinary tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24307946" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15150380" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27313263" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21761126" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26416859" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23917908" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27532362" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Fluoroquinolone-Resistant and Extended-Spectrumβ-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23926177" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23926176" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4105942" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Site of infection in acute urinary-tract infection in general practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37499555" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical factors distinguishing renal infarction from acute pyelonephritis: A randomly matched retrospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15374159" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28624753" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25117748" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592413" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31449295" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36436954" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : ACR Appropriateness Criteria®Acute Pyelonephritis: 2022 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651759" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Frequency of development of early cortical scarring in acute primary pyelonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12848478" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Radiologic evaluation of patients with renal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388315" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Computerized tomography in acute pyelonephritis: the clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388315" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Computerized tomography in acute pyelonephritis: the clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388315" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Computerized tomography in acute pyelonephritis: the clinical correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17318482" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : State of the art: imaging of renal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2798873" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sequelae of acute renal infections: CT evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1996820" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Treatment of pyelonephritis in an observation unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23939900" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26243291" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707990" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27107460" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29486041" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786187" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Once-Daily Plazomicin for Complicated Urinary Tract Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30861061" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35024838" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35024838" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1987461" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Fluoroquinolone antimicrobial agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22252813" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10735395" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18242357" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14713799" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22726802" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22729920" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11777865" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30662274" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35388666" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28666756" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): a single-center university hospital experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26369973" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Outcomes of Aminopenicillin Therapy for Vancomycin-Resistant Enterococcal Urinary Tract Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476003" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Incidence and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16619173" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Methicillin-resistant Staphylococcus aureus bacteremia after isolation from urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29129031" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Evaluation and management of Staphylococcus aureus bacteriuria: an updated review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22417256" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical practice. Uncomplicated urinary tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892331" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36633559" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23696620" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32566969" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29679383" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28366170" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36785526" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9098661" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A practical guide to the management of complicated urinary tract infection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
